Clinical trials: Aspergillus Infection
Invasive Aspergillosis, Pleural Effusion
Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing
Diagnostic accuracy of biomarker testing (galactomannan (GM), (1
- Conditions
- Invasive Aspergillosis, Pleural Effusion, Immunosuppression
- Trial name
- EFFU-ASP (NCT02104479)
- Where
- 2 sites in Germany
- Volunteers
- 200 people
- Sponsor
- Heidelberg University
Chronic Pulmonary Aspergillosis
Impact of Chronic Pulmonary Aspergillosis (CPA) on Health Status and Well-being
To develop and validate a novel disease-specific questionnaire for measuring HRQoL in patients with Chronic Pulmonary Aspergillosis (CPA-HAQ) for use in clinical research, including clinical trials.
- Trial name
- CAPSULE (NCT06885905)
- Where
- 3 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- Imperial College London
Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis
Natural History of Individuals With Immune System Problems That Lead to Fungal Infections
Background: The immune system is made up of special cells, tissues, and organs that fight infections. Problems with this system may lead to frequent, severe, or unusual fungal infections.
- Conditions
- Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis, CARD9, APECED
- Trial name
- NCT01386437
- Where
- United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Invasive Aspergillosis
Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects
Double blind, placebo controlled, ascending multiple (10) oral dose, sequential group study. Twenty-four subjects will complete the study in 3 cohorts (Groups A to C), each group consisting of 8 subjects.
- Trial name
- ORALMAD (NCT02737371)
- Testing
- F901318 Dose level A oral, F901318 Dose level B oral, F901318 Dose level C oral
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Invasive Pulmonary Aspergillosis, COPD
Voriconazole for IPA in Chinese Patients With COPD
voriconazole is recommended as first-line therapy for invasive pulmonary aspergillosis, however the efficacy and safety of voriconazole for treating invasive pulmonary aspergillosis secondary to COPD is not clear.
- Trial name
- VIA-COPD (NCT02234739)
- Testing
- Voriconazole
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Red Cross Hospital, Hangzhou, China
Chronic Pulmonary Aspergillosis, CPA
A Trial to Compare Nebulized Amphotericin B and Nebulized Normal Saline as Maintenance in Patients With Chronic Pulmonary Aspergillosis
The treatment of CPA is with oral itraconazole for 6-12 months. Oral itraconazole results in better clinical outcomes in CPA compared to supportive care.
- Conditions
- Chronic Pulmonary Aspergillosis, CPA, Aspergilloma
- Trial name
- NAB-CPA (NCT06447402)
- Testing
- Normal saline, Amphotericin B deoxycholate
- Where
- India
- Volunteers
- 196 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Aspergillosis
A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).
The combination of Anidulafungin plus AmBisome® may offer an improved outcome for patients treated for Invasive Aspergillosis (IA).
- Trial name
- NCT00037206
- Testing
- Anidulafungin, VER002
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Pfizer
Invasive Aspergillosis
F901318 Multiple Ascending Dose Study
Double blind, placebo controlled, parallel group ascending dose study evaluating single and multiple (x8 days) dose levels of F901318 in groups of male healthy subjects with the objective of defining a dosing schedule for phase…
- Trial name
- NCT02342574
- Testing
- F901318
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Pulmonary Aspergillosis, Chronic Pulmonary Aspergillosis
iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine
This is a single center open-label feasibility trial involving a single study visit for participants. The purpose of the study is to demonstrate the feasibility of [68Ga]Ga-DFO-B PET/CT (gallium-68-deferoxamine) for the…
- Conditions
- Pulmonary Aspergillosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis
- Trial name
- MIRAGE (NCT06244979)
- Testing
- Radiopharmaceutical: gallium-68-deferoxamine ([68Ga]Ga-DFO-B)
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Radboud University Medical Center
Invasive Pulmonary Aspergillosis, Breath Samples
VOC in Breath Samples for the Diagnosis of IPA
The diagnosis of invasive pulmonary aspergillosis (IPA) bears grave implications for the prognosis and treatment plan of the immunosuppressed patient.
- Conditions
- Invasive Pulmonary Aspergillosis, Breath Samples, Volatile Organic Compounds
- Trial name
- NCT05982912
- Testing
- breath sampling
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- Rambam Health Care Campus
Invasive Fungal Infections
Non-interventional Study for Prevention and Treatment of Fungal Infections in Paediatric Patients in Asia/Oceania - ERADICATE Study
The aim of the study is to prospectively evaluate the safety and efficacy of micafungin when prescribed for prophylaxis or treatment of fungal infections in different real-world clinical conditions and centers, in pediatric…
- Trial name
- NCT03174457
- Testing
- Micafungin
- Where
- 16 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 120 people
- Sponsor
- Astellas Pharma Singapore Pte. Ltd.
Cystic Fibrosis, Aspergillosis
A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection
This study will provide: (1) new insights in the prevalence of Aspergillus infection in children and adolescents with CF aged 8-17 yrs; (2) an in silico modelled dose of posaconazole for children and adolescents with CF and…
- Trial name
- cASPerCF (NCT04966234)
- Testing
- Posaconazole 100 MG [Noxafil], Posaconazole 40 MG/ML
- Where
- 31 sites in Czechia, France and 9 more
- Volunteers
- 135 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Invasive Aspergillosis, Mucormycosis
A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions.
This is a non-interventional medical chart review study aiming to examine the effectiveness, safety, and treatment patterns of isavuconazole in 5 European countries (France, Germany, Italy, Spain, and United Kingdom).
- Trial name
- PRISMA (NCT04550936)
- Testing
- Isavuconazole
- Where
- 15 sites in France, Germany and 3 more
- Volunteers
- 307 people
- Sponsor
- Pfizer
Invasive Candidiasis, Invasive Aspergillosis
A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus
This is a multi-center, open-label, non-controlled, single-arm clinical trial to evaluate the safety, efficacy and population pharmacokinetics of Amphotericin B cholesteryl Sulfate Complex for Injection domestic formulations…
- Trial name
- NCT05707832
- Testing
- Amphotericin B cholesteryl Sulfate Complex for Injection
- Where
- China
- Volunteers
- 31 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Graft Versus Host Disease, Infection
Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other Disease
RATIONALE: Studying ways to diagnose fungal infections early may help doctors plan the best treatment. PURPOSE: This clinical trial is studying laboratory tests to see how well they find aspergillosis early in patients at high…
- Conditions
- Graft Versus Host Disease, Infection, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00462657
- Testing
- polymerase chain reaction, bronchoalveolar lavage, immunoenzyme technique
- Where
- 2 sites in United Kingdom
- Volunteers
- 200 people
- Sponsor
- St. Bartholomew's Hospital
Mycoses
PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893)
This phase II study will be conducted to: 1. evaluate the pharmacokinetics, safety, tolerance, and efficacy of different dosing schedules of Posaconazole in immunocompromised hosts with a variety of refractory invasive fungal…
- Trial name
- NCT00034671
- Testing
- Posaconazole oral suspension
- Volunteers
- 98 people
- Sponsor
- Merck Sharp & Dohme LLC
Covid-19
Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU
Characterization of fungal infections in COVID-19 infected and mechanically ventilated patients in ICU
- Trial name
- MY-CO-VID (NCT04368221)
- Where
- 22 sites in France
- Volunteers
- 576 people
- Sponsor
- Rennes University Hospital
ABPA
Cytokine Profile of Allergic Bronchopulmonary Aspergillosis
The main aim of this study is to determine whether the levels of different inflammatory cytokines in the serum and BALF (bronchoalveolar lavage fluid) are relative to the severity and exacerbations of ABPA (allergic…
- Trial name
- NCT03643185
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Fungal Infection
A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED)
The purpose of this study is to investigate the safety and efficacy of MK0991 in patients with deep-seated mycoses.
- Trial name
- NCT00717860
- Testing
- caspofungin acetate, Comparator: Micafungin sodium
- Volunteers
- 121 people
- Sponsor
- Merck Sharp & Dohme LLC
Invasive Aspergillosis
Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects
A Phase I, open label study evaluating safety, tolerability and pharmacokinetics of F901318 in healthy subjects following up to 28 days dosing, where F901318 is given orally .
- Trial name
- NCT03340597
- Testing
- F901318
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- F2G Ltd